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PODIUM SESSION II:  
INFECTIOUS DISEASE OUTCOMES RESEARCH STUDIES  
 
IN1  
INTERVIEWS WITH PATIENTS WITH CHRONIC HEPATITIS C (CHC) VIRUS 
INFECTION DOCUMENT UNMET NEEDS, CONTENT VALIDITY, AND 
COMPREHENSION OF PROS FOR CLINICAL TRIALS  
Blackburn S1, McCool R1, Panter C1, Young V1, Peterson S2, Mitchell L2, Machouf N3,  
Scott J4, Humphrey L1 
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OBJECTIVES: Recent advances in treatment for chronic hepatitis C (CHC) virus 
infection have shortened duration of treatment and increased the likelihood of 
treatment success. To understand what unmet needs remain with available CHC 
treatments, patient interviews explored what it is like to live with CHC infection 
and undergo CHC treatment. A subset of interviews also evaluated the content 
validity and comprehension of patient-reported outcome (PRO) questionnaires 
for use in CHC clinical trials. METHODS: Sixty-five patients with clinician-
confirmed diagnosis of CHC infection provided informed consent and completed 
interviews in Germany (n=15), France (n=15), the USA (n=16), and Canada (n=19). 
Targeted sampling enrolled a demographically and clinically diverse sample. 
Concept elicitation (CE) interviews (n=58) using in-depth, open-ended 
questioning encouraged spontaneous discussion of patients’ experience of CHC 
and its treatment. Patients in the USA and Canada also completed cognitive 
debriefing (CD) interviews using a ‘think aloud’ protocol to evaluate content 
validity and comprehension of the Fatigue Severity Scale (FSS, n=34), Work 
Productivity and Activity Impairment questionnaire for Hepatitis C 
(WPAI:Hepatitis C, n=7) and the SKINDEX-16 (n=12). Verbatim transcripts were 
translated to English and analyzed using thematic analysis. RESULTS: 
Treatment-related symptoms cause a significant burden for patients during 
treatment with tiredness (60.0%), sleep problems (57.5%), fatigue (50.0%), 
depression (45.0%) and itchy skin (40.0%) among the most commonly reported 
symptoms mentioned in CE interviews. In the 40 patients with CHC treatment 
experience, treatment-related symptoms led to discontinuation or lack of 
adherence in 25% and 10%, respectively. CD interviews confirmed that the 
questionnaires were relevant, understandable and easy to complete. Patients 
suggested minor wording changes that may make these questionnaires easier to 
complete. CONCLUSIONS: Treatment-related symptoms cause a significant 
burden for CHC patients and affect their adherence to treatment. The FSS, 
WPAI:Hepatitis C, and SKINDEX-16 are valid tools for PRO assessment in CHC 
clinical trials.  
 
IN2  
CLINICAL CHARACTERISTICS AND TREATMENT DURATION AMONG PATIENTS 
WITH CHRONIC HEPATITIS C VIRUS (HCV) INFECTION INITIATING DIRECT-
ACTING ANTIVIRAL THERAPY IN A LARGE COMMERCIAL INSURANCE 
DATABASE IN THE UNITED STATES  
Bonafede MM1, Suthoff ED2, Eynullayeva E1 
1Truven Health Analytics, Cambridge, MA, USA, 2Vertex Pharmaceuticals, Inc., Cambridge, MA, USA  
OBJECTIVES: To describe patient characteristics and treatment duration among 
patients initiating telaprevir (T) or boceprevir (B) combination treatments with 
pegylated interferon and ribavirin (T/PR; B/PR) using administrative claims data. 
METHODS: A retrospective analysis of data from patients initiating T/PR or B/PR 
(index date) was conducted (MarketScan Research Databases 2011-2012). Study 
criteria included 7 months of continuous enrollment pre-index, 6 months post-
index, diagnosis of chronic HCV and claim for PR within 40 days of index date. 
Pre-index comorbidities were ascertained using ICD-9-CM codes. Indicated T 
duration is 12 weeks (84 days); and minimum indicated B duration is 24 weeks 
(168 days; maximum 44 weeks). Medication Possession Ratios (MPR, adherence 
indicator) and persistence were estimated over the indicated duration of 
treatment for each drug respectively. RESULTS: A total of 3288 patients met the 
study criteria (T/PR, n=2582 [79%]; and B/PR, n=706 [21%]). Age (mean±SD) and 
gender were similar between cohorts (T/PR=53.7±8.4 years, 35% female; 
B/PR=53.7±8.7 years, 39% female). Patients treated with T/PR were more likely to 
have a claim for liver cirrhosis in the pre-index period (T/PR=24%; B/PR=18%, 
p=0.002). Prevalence rates of other comorbidities were similar between cohorts: 
diabetes (T/PR=14%; B/PR=13%), hypertension (T/PR=12%; B/PR=12%), and anxiety 
or depression (T/PR=11%; B/PR=11%). MPR (mean±SD) was 0.91±0.2 for T/PR 
patients in the first 84 days post-index and 0.78±0.3 for B/PR in the first 168 days 
post-index (p<0.001). At 84 days, 82% (95% confidence interval [CI]: 80%-83%) of 
T/PR patients were on therapy compared with 84% (CI: 81%-87%) of B/PR patients; 
54% (CI: 51%-58%) of B/PR patients were still on therapy at 168 days. 
CONCLUSIONS: Chronic HCV-infected patients initiating telaprevir or boceprevir 
combination treatment had similar demographic characteristics and non-liver 
comorbidities. Cirrhosis was more prevalent among patients receiving telaprevir 
combination treatment. Data suggest adherence to indicated duration of 
treatment was higher among telaprevir patients than boceprevir patients.  
 
IN3  
THE BURDEN OF HCV TO INSURERS IN THE UNITED STATES: TRENDS IN 
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OBJECTIVES: Trends in health care utilization among HCV patients have 
demonstrated marked increases between 1994 and 2001, particularly among 
individuals aged 40 to 60 years. Furthermore, the proportion of treated 
individuals who achieve disease cure remains relatively low. This has potentially 
resulted in a large economic burden, as HCV leads to costly liver disease and 
other morbidity. The objective of this study was to examine trends in HCV-
related health care utilization by insurer between 2002 and 2010 in the US. 
METHODS: Years 2002-2010 of the National Inpatient Sample (NIS) data set of 
hospital admissions from the Healthcare Cost and Utilization Project (HCUP) 
were utilized in order to determine the number of adult hospital admissions 
occurring to HCV-infected patients (identified by ICD-9 codes). These data 
included a total of 71.7 million hospital admissions from 1,051 US hospitals. The 
number of admissions occurring to HCV-infected patients was recorded for each 
year, as well as total charges. Trends over time were compared for three 
insurers: Medicaid, Medicare, and private. RESULTS: Of the 71 million 
admissions examined over the study period, 5,350,991 were admissions for HCV-
infected adults. More HCV-related admissions were covered by Medicaid and 
Medicare than private insurance. In 2002, total HCV-related charges were $693M 
for admissions covered by Medicare, $708M for Medicaid, and $579M for private 
insurance (costs adjusted to 2010 values). Between 2002 and 2010, total HCV-
related charges increased most for Medicare (84%), followed by Medicaid (77%) 
and private insurance (16%). HCV-related admissions covered by Medicare, 
Medicaid and private insurance increased commensurately by 84%, 77% and 16%, 
respectively. CONCLUSIONS: Use of inpatient care for HCV-infected patients has 
increased rapidly. Increases in the number of HCV patients who seek care, as 
well as possible increases in the intensity of care and/or escalation in hospital 
charges has resulted in nearly doubling HCV-related charges from 2002-2010.  
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OBJECTIVES: To assess the direct health care and indirect work-loss cost burden 
of chronic hepatitis C virus (HCV) infection and stratify the economic burden by 
disease severity. METHODS: Health insurance claims from 60 self-insured US 
companies and disability data for employees in 29 of these companies covering 
the period 01/2001-09/2011 were analyzed. Adult patients with ≥2 diagnosis 
claims of chronic HCV infection and no HIV diagnosis were selected. A 6-month 
baseline period of continuous eligibility preceding HCV diagnosis was imposed. 
HCV patients were stratified into groups of non-cirrhotic, compensated cirrhotic, 
and end-stage liver disease (ESLD). HCV patients were matched 1:1 with non-
HCV controls using an exact factors and propensity score matching algorithm. 
Matched cohorts were compared for direct (pharmacy dispensings and medical 
services) and indirect (disability and medically related absenteeism) costs using 
per-patient per-year (PPPY) cost differences. RESULTS: Both cohorts (N=9,841 for 
each) were well matched with respect to age (mean=52 years), gender 
(female=39%), Quan-Charlson comorbidity index (mean=0.5), share of employees 
with disability coverage (26%), and non-HCV related co-morbidities. HCV patients 
incurred significantly greater direct and indirect costs relative to non-HCV 
patients (PPPY direct costs: $16,721 vs. $6,063, cost difference [95% CI] = $10,503 
[9,683-11,361], P<0.001; PPPY indirect costs: $3,310 vs. $1,723, cost difference [95% 
CI] = $1,523 [1,248-1,794], P<0.001). The direct incremental cost burden associated 
with HCV increased with disease severity (incremental direct cost [95% CI]: non-
cirrhotic HCV = $5,536 [4,844-6,333]; compensated cirrhotic = $6,833 [5,326-8,474]; 
ESLD = $22,466 [20,182-24,729], P<0.001 for all comparisons versus matched non-
HCV controls in each sub-category). Among the subset of employees with 
disability coverage, the incremental indirect cost burden associated with HCV 
also increased with disease severity. CONCLUSIONS: Chronic HCV infection was 
associated with significant direct health care and indirect work-loss cost 
burdens. The magnitude of the cost burden increased with disease severity.  
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MA1  
IMPACT OF A VALUE-BASED COPAYMENT WAIVER BENEFIT ON MEDICATION 
ADHERENCE AND SPENDING  
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OBJECTIVES: Most copayment waiver (value-based benefit design) programs 
have been applied at the individual level. In this study we evaluate the impact of 
a family-based copayment waiver at a large employer. METHODS: Enrollees with 
diabetes in eligible health and all of their family members (regardless of health 
status) were automatically enrolled in a copayment waiver ($0 copay) benefit 
beginning January 2011 for diabetes, cardiovascular, and lipid lowering 
medications, screenings, and related medical services. The study included 708 
enrollees who were propensity score matched to a comparison group (total 
n=1416) within nine similar companies without these benefits. An enrollee-
calendar quarter panel data set was constructed from 2009-2011. Program impact 
was measured as the change in outcomes (medication adherence and health 
care spending) post-program in the copayment waiver group relative to the 
change in the comparison group (difference-in-differences). Adherence was 
defined as percent of days covered by a medication class greater than or equal to 
80%. A falsification test of adherence to asthma and migraine medications, 
where copayments did not change, was conducted. RESULTS: Prior to program 
implementation, enrollees in the value-based program had a similar level of 
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adherence to diabetes medications than the comparison group (p=0.15). After the 
program, percent adherent grew 29.7% over baseline (p<0.01) net of trends in the 
comparison group. A smaller impact was observed for cardiovascular 
medications. Total spending (employer spending plus patient out-of-pocket 
spending) in the value-based program group was no different than the 
comparison group (p=0.11). Falsification tests of asthma and migraine 
medication utilization, showed no significant impact (p>.50). CONCLUSIONS: 
Results through the first twelve months of the program show that waiving 
copayments for all family members of a patient with diabetes can improve 
adherence to diabetes and cardiovascular services, which can lead to 
improvements in health outcomes.  
 
MA2  
BEYOND AVERAGE ADHERENCE: TEMPORAL PATTERNS OF MEDICATION 
ADHERENCE PREDICT HOSPITALIZATION RISK MORE ACCURATELY THAN THE 
MEDICATION POSSESSION RATIO  
Signorovitch J, Chopra P, Cheng D, Ayyagari R, Wu EQ 
Analysis Group, Inc., Boston, MA, USA  
OBJECTIVES: A patient’s temporal pattern of medication adherence may contain 
signals for clinical risks that are not captured by aggregate measures such as the 
medication possession ratio (MPR). We used hierarchical clustering to identify 
natural adherence patterns to dornase alfa in patients with cystic fibrosis (CF), 
and assessed whether these patterns were associated with hospitalization risk. 
METHODS: CF patients with a dornase alfa prescription followed by ≥1 year of 
health plan enrollment were identified in a national claims database (2005 - 
2011). Hierarchical clustering was used to identify common patterns of 
adherence over time based on prescription fills. To evaluate the clinical and 
economic meaningfulness of the clusters, their association with CF-related 
hospitalization risk was assessed using Poisson regression with adjustment for 
MPR and other characteristics. RESULTS: A total of 985 CF patients with ≥1 
prescription for dornase alfa were included. Average MPR was 45%. Half of the 
patients experienced hospitalization. Clustering identified six adherence 
patterns: 1) high; 2) low→high; 3) low →lower; 4) high→ow; 5) periodic; and 6) 
low. MPR distributions overlapped between clusters. In the Poisson regression, 
each 1% increase in MPR was significantly (p<0.05) associated with an 
approximate 1% reduction in hospitalization risk. Including effects of cluster 
membership into the model with MPR significantly improved fit (P<0.001). Even 
after adjusting for MPR, hospitalization risk varied significantly across clusters, 
and, relative to cluster 1, was increased by 97%, 115%, 52%, 286% and 57% in 
clusters 2 through 6, respectively. The predictive significance of the clusters was 
robust to further adjustment for quadratic effects of MPR. CONCLUSIONS: In this 
study of CF patients, temporal patterns of medication adherence predicted 
hospitalization risk more accurately than MPR alone. Temporal adherence 
patterns beyond MPR may have clinical and economic utility across therapeutic 
areas and warrant further study.  
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REVISION AND VALIDATION OF THE MEDICATION ADHERENCE REASONS 
SCALE (MAR –SCALE)  
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OBJECTIVES: Medication non-adherence is a complex phenomenon that requires 
tailored interventions to improve it. A new self-reported measure of medication 
non-adherence was developed based on the commonly reported reasons 
underlying non-adherence. The goal of the new scale was to match the items in 
the scale with tailored interventions. The objectives of this study were to revise 
the original Medication Adherence Reasons Scale (MAR-Scale) based on expert 
opinion and cognitive interviewing and establish the psychometric properties of 
the scale. METHODS: A cross sectional design was used in collaboration with the 
Intermountain Medical Center Outpatient clinic for cholesterol lowering (CLM) 
and asthma maintenance medications (AMM). The study was conducted in two 
phases: Phase 1 - the original MAR-Scale was revised based on expert opinion 
and cognitive interviewing, Phase 2 - the revised MAR-Scale was tested for 
psychometric properties in a random sample of 350 subjects each on CLM and 
AMM. RESULTS: Revisions were made based on expert opinion that included 
asking a global question about adherence in the past 7 days, simplifying the 
items and converting them into first person sentences, objective anchoring of 
the scale, and expanding the “forgetfulness” item. Cognitive interviewing added 
one additional item to the survey. The MAR- Scale identified 48% of the CLM 
respondents and 65% of the AMM respondents as non-adherents. An exploratory 
factor analysis identified four domains in each medication with Cronbach alpha 
ranging from 0.848 to 0.953 in CLM and 0.827 to 0.891 in AMM. For validity, the 
scale exhibited significant correlations (0.434 for CLM and 0.539 for AMM at 
p<0.01) with the well validated Morisky scale and also had significant negative 
correlation with self-efficacy (-0.226 for CLM and -0.329 for AMM at p < 0.01). 
CONCLUSIONS: The study resulted in a revised MAR-Scale that demonstrated 
better psychometric properties than the original scale.  
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OBJECTIVES: It is well-established that patients’ medication adherence is often 
suboptimal and variable in chronic disease settings, but less is known about the 
association between adherence and outcomes, in part due to potential 
confounding by unobserved disease severity when using claims data. Our 
objective was to estimate adherence unexplained by observed characteristics 
and use this estimate to proxy severity, which could motivate better adherence 
but also worsen outcomes. METHODS: A sample of the IMS LifeLink Health Plan 
Claims Database was used to identify a cohort of 26,893 primary prevention 
statin users. Adherence was estimated as the yearly proportion of days covered 
in beginning with the index statin prescription. A finite mixture model (FMM) 
was used to predict a posteriori the membership to better or worse adherer types. 
Using OLS regression adjusting for patient characteristics and the ‘healthy 
adherer effect’, the determinants of this probability were estimated. A residual 
inclusion estimation approach was used in a Cox proportional hazards model to 
estimate the effect of adherence on cardiovascular events. RESULTS: In a sample 
of new statin users, groups of low- and high-adherers existed. While year one 
adherence was not associated with cardiovascular events, year two mean 
adherence was (0.49 vs. 0.46, P<0.001). In the second year of statin use, the 
probability of being a high-adherer increased for males, those over 65 years and 
‘healthy adherers’. The Cox model adjusting for the covariates and residuals 
showed that as year two adherence increased, CV hazard decreased by 38% 
(P>0.001), versus a 20% reduction when the residual was not included. The 
included residuals per se increased hazard by 28% (P=0.04), consistent with a 
disease severity effect. CONCLUSIONS: FMM estimation reveals adherence 
‘types’. Estimating the probability of the ‘type’ allows isolation of a measure to 
address unobserved characteristics, such as disease severity, when modeling 
outcomes.  
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MODELING FUTURE PREVALENCE OF NEUROLOGICAL CONDITIONS AND 
DEMAND FOR PHARMACEUTICALS IN THE UNITED STATES  
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OBJECTIVES: Accurately forecasting future disease prevalence and resulting 
demand for pharmaceuticals requires modeling changes in demographics, 
economic considerations, health care policy, disease risk factors, and treatment 
options. This study forecasts future neurological condition prevalence and 
related use of prescribed medications. METHODS: Using a microsimulation 
approach, we model future prevalence of neurological conditions and 
pharmaceutical use for each person in a stratified random sample (n~3M) of the 
population in the United States. The population database uses statistical 
matching to combine (1) population and economic data from the American 
Community Survey, (2) health data from the Behavioral Risk Factor Surveillance 
System, and (3) health data from National Nursing Home Survey. Sample 
weighting is derived from Census Bureau population projections. Logistic 
regression analysis with the Medical Expenditure Panel Survey estimates the 
propensity of people with neurological conditions to use prescribed medications 
to treat Alzheimer’s, attention deficit hyperactivity disorder, cerebral 
degeneration, epilepsy, extrapyramidal disease not elsewhere classified, mental 
retardation, migraine, mononeuritis of limb, multiple sclerosis, Parkinson’s, and 
sleep disorders. Forecasts through 2030 consider household income and 
demographic trends, and improved medical coverage under health care reform. 
RESULTS: In 2012, 26.6 million people (9% of US population) had a diagnosed 
neurological condition. Between 2012 and 2030, the population with neurological 
conditions will grow by 17% with the largest percentage growth occurring in 
Arizona (62% growth), Nevada (56%), and Florida (55%). Conditions with the 
largest percentage growth in prevalence are cerebral degeneration (72% growth), 
Parkinson’s disease (60%) and Alzheimer’s disease (59%). Use of medications will 
grow 2-3% through expanded medical coverage under PPACA. CONCLUSIONS: 
Prevalence rates for diagnosed and treated neurological conditions are projected 
to grow at similar rates over the next 20 years. Given the large increase in 
prevalence, the utilization of treatments (e.g., levodopa, MAOIs, cholinesterase 
inhibitors, and memantine) will rise accordingly.  
 
MO2  
REANALYZING CAROTID ARTERY STENOSIS TREATMENT CLINICAL TRIAL 
RESULTS FROM A BAYESIAN PERSPECTIVE  
Smolen HJ 
Medical Decision Modeling Inc., Indianapolis, IN, USA  
Frequentist statistics typically examines the null hypothesis that no difference 
exists between the competing strategies. Bayesian statistics permits the 
calculation of the probability that a treatment is superior based on observed data 
and prior information. Output of Bayesian analysis allows the observation of 
how prior information affects the output, especially as new information builds 
on the prior information. OBJECTIVES: To further analyze using Bayesian 
methods clinical trial results for the treatment of asymptomatic carotid artery 
stenosis (surgery vs. medical management) whose results were previously 
reported using frequentist methods. METHODS: The outcome of interest was the 
mean difference in the probability of stroke or perioperative death between 
carotid endarterectomy (CEA) and aggressive medical management (AMM). The 
prior distribution came from the results of the Asymptomatic Carotid 
Atherosclerosis Study (ACAS). The likelihood distribution was sourced from the 
Asymptomatic Carotid Surgery Trial (ACST). The Metropolis-Hastings Markov 
chain Monte Carlo sampling algorithm was used to approximate the posterior 
distribution. A 4% mean difference was chosen as the threshold for clinical-
economic significance. In sensitivity analysis, the prior distribution was replaced 
with results of The European Carotid Surgery Trialists Collaborative Group (ECST) 
study. RESULTS: The likelihood distribution (ASCT results) had an 86.5% 
